Transcriptomics,Genomics

Dataset Information

44

A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Breast Cancer


ABSTRACT: This phase II study examined the pathological complete response (pCR) rate and safety of two gemcitabine-based combinations administered sequentially in breast cancer. We also examined gene expression profiles from tumor biopsies to identify biomarkers predictive of response. Methods: Indian women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200 mg/m2 plus doxorubicin 60 mg/m2 (Gem+Dox), then 4 cycles of gemcitabine 1000 mg/m2 plus cisplatin 70 mg/m2 (Gem+Cis), and surgery. To examine dynamic changes in molecular profiles after one dose of therapy, we used three alternate sequences during cycle 1 (Gem d1, 8; Dox d2; Gem d1, 8; Dox d1; or Gem d2, 8; Dox d1). Results: Of 65 women (median age 46) treated, 13 (24.5% of 53 patients with surgery) had a pCR and 22 (33.8%) had a complete clinical response. Patients who received Gem d1, 8 and Dox d2 in cycle 1 (20/65) reported more toxicities, with G3/4 neutropenic infection/febrile neutropenia (7/20) and vomiting (5/20) as the most common cycle 1 events. Four drug-related deaths occurred. 46/65 patients yielded successful pretreatment gene expression profiles. Ten-fold cross-validated supervised analyses identified gene expression patterns that predicted with >73% accuracy (1) clinical complete response after eight cycles, (2) overall clinical complete response, and (3) pCR. Conclusions: This neoadjuvant regimen showed strong activity. A subset of patients receiving Gem d1, 8 and Dox d2 experienced unacceptable toxicity, whereas patients on other sequences had more manageable safety profiles. The predictive gene expression patterns may provide a method for selecting patients most likely to benefit from gemcitabine-containing neoadjuvant therapy. Key words: breast cancer, chemotherapy, gemcitabine, , gene expression, microarrays, neoadjuvant therapy Keywords: Dose response Overall design: This phase II study examined the pathological complete response (pCR) rate and safety of two gemcitabine-based combinations administered sequentially in breast cancer

INSTRUMENT(S): Agilent-012097 Human 1A Microarray (V2) G4110B (Feature Number version)

SUBMITTER: Charles M. Perou  

PROVIDER: GSE8465 | GEO | 2008-01-12

SECONDARY ACCESSION(S): PRJNA101549

REPOSITORIES: GEO

altmetric image

Publications

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling.

Julka P K PK   Chacko R T RT   Nag S S   Parshad R R   Nair A A   Oh D S DS   Hu Z Z   Koppiker C B CB   Nair S S   Dawar R R   Dhindsa N N   Miller I D ID   Ma D D   Lin B B   Awasthy B B   Perou C M CM  

British journal of cancer 20080401 8


This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour biopsies to identify biomarkers predictive of response. Indian women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200 mg m(-2) plus doxorubicin 60 mg m(-2) (Gem+Dox), then 4 cycles of gemcitabine 1000 mg m(-2) plus cisplatin 70 mg m(-2) (Gem+Cis), and surgery. Three alter  ...[more]

Similar Datasets

| GSE80617 | GEO
| GSE79234 | GEO
| GSE80616 | GEO
| GSE63139 | GEO
| GSE63138 | GEO
2017-01-20 | E-MTAB-4927 | ArrayExpress
2015-05-01 | E-GEOD-58118 | ArrayExpress
| GSE121199 | GEO
2013-01-01 | E-GEOD-41998 | ArrayExpress
2015-01-21 | E-GEOD-48073 | ArrayExpress